1
|
Biological activity-based modeling identifies antiviral leads against SARS-CoV-2. Nat Biotechnol 2021; 39:747-753. [PMID: 33623157 PMCID: PMC9843700 DOI: 10.1038/s41587-021-00839-1] [Citation(s) in RCA: 33] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2020] [Accepted: 01/25/2021] [Indexed: 01/29/2023]
Abstract
Computational approaches for drug discovery, such as quantitative structure-activity relationship, rely on structural similarities of small molecules to infer biological activity but are often limited to identifying new drug candidates in the chemical spaces close to known ligands. Here we report a biological activity-based modeling (BABM) approach, in which compound activity profiles established across multiple assays are used as signatures to predict compound activity in other assays or against a new target. This approach was validated by identifying candidate antivirals for Zika and Ebola viruses based on high-throughput screening data. BABM models were then applied to predict 311 compounds with potential activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Of the predicted compounds, 32% had antiviral activity in a cell culture live virus assay, the most potent compounds showing a half-maximal inhibitory concentration in the nanomolar range. Most of the confirmed anti-SARS-CoV-2 compounds were found to be viral entry inhibitors and/or autophagy modulators. The confirmed compounds have the potential to be further developed into anti-SARS-CoV-2 therapies.
Collapse
|
2
|
Huang R, Xu M, Zhu H, Chen CZ, Lee EM, He S, Shamim K, Bougie D, Huang W, Hall MD, Lo D, Simeonov A, Austin CP, Qiu X, Tang H, Zheng W. Massive-scale biological activity-based modeling identifies novel antiviral leads against SARS-CoV-2. BIORXIV : THE PREPRINT SERVER FOR BIOLOGY 2020. [PMID: 32766591 DOI: 10.1101/2020.07.27.223578] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
The recent global pandemic caused by the new coronavirus SARS-CoV-2 presents an urgent need for new therapeutic candidates. While the importance of traditional in silico approaches such as QSAR in such efforts in unquestionable, these models fundamentally rely on structural similarity to infer biological activity and are thus prone to becoming trapped in the very nearby chemical spaces of already known ligands. For novel and unprecedented threats such as COVID-19 much faster and efficient paradigms must be devised to accelerate the identification of new chemical classes for rapid drug development. Here we report the development of a new biological activity-based modeling (BABM) approach that builds on the hypothesis that compounds with similar activity patterns tend to share similar targets or mechanisms of action. In BABM, compound activity profiles established on massive scale across multiple assays are used as signatures to predict compound activity in a new assay or against a new target. We first trained and validated this approach by identifying new antiviral lead candidates for Zika and Ebola based on data from ~0.5 million compounds screened against ~2,000 assays. BABM models were then applied to predict ~300 compounds not previously reported to have activity for SARS-CoV-2, which were then tested in a live virus assay with high (>30%) hit rates. The most potent compounds showed antiviral activities in the nanomolar range. These potent confirmed compounds have the potential to be further developed in novel chemical space into new anti-SARS-CoV-2 therapies. These results demonstrate unprecedented ability using BABM to predict novel structures as chemical leads significantly beyond traditional methods, and its application in rapid drug discovery response in a global public health crisis.
Collapse
|
3
|
Roth JS, Lee TD, Cheff DM, Gosztyla ML, Asawa RR, Danchik C, Michael S, Simeonov A, Klumpp-Thomas C, Wilson KM, Hall MD. Keeping It Clean: The Cell Culture Quality Control Experience at the National Center for Advancing Translational Sciences. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2020; 25:491-497. [PMID: 32233736 PMCID: PMC8506661 DOI: 10.1177/2472555220911451] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Quality control monitoring of cell lines utilized in biomedical research is of utmost importance and is critical for the reproducibility of data. Two key pitfalls in tissue culture are 1) cell line authenticity and 2) Mycoplasma contamination. As a collaborative research institute, the National Center for Advancing Translational Sciences (NCATS) receives cell lines from a range of commercial and academic sources, which are adapted for high-throughput screening. Here, we describe the implementation of routine NCATS-wide Mycoplasma testing and short tandem repeat (STR) testing for cell lines. Initial testing identified a >10% Mycoplasma contamination rate. While the implementation of systematic testing has not fully suppressed Mycoplasma contamination rates, clearly defined protocols that include the immediate destruction of contaminated cell lines wherever possible has enabled rapid intervention and removal of compromised cell lines. Data for >2000 cell line samples tested over 3 years, and case studies are provided. STR testing of 186 cell lines with established STR profiles revealed only five misidentified cell lines, all of which were received from external labs. The data collected over the 3 years since implementation of this systematic testing demonstrate the importance of continual vigilance for rapid identification of "problem" cell lines, for ensuring reproducible data in translational science research.
Collapse
Affiliation(s)
- Jacob S. Roth
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Tobie D. Lee
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Dorian M. Cheff
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Maya L. Gosztyla
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Rosita R. Asawa
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Carina Danchik
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Sam Michael
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Anton Simeonov
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Carleen Klumpp-Thomas
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Kelli M. Wilson
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Matthew D. Hall
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| |
Collapse
|
4
|
Lee OW, Austin S, Gamma M, Cheff DM, Lee TD, Wilson KM, Johnson J, Travers J, Braisted JC, Guha R, Klumpp-Thomas C, Shen M, Hall MD. Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. SLAS DISCOVERY : ADVANCING LIFE SCIENCES R & D 2020; 25:9-20. [PMID: 31498718 PMCID: PMC10791069 DOI: 10.1177/2472555219873068] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Cell-based phenotypic screening is a commonly used approach to discover biological pathways, novel drug targets, chemical probes, and high-quality hit-to-lead molecules. Many hits identified from high-throughput screening campaigns are ruled out through a series of follow-up potency, selectivity/specificity, and cytotoxicity assays. Prioritization of molecules with little or no cytotoxicity for downstream evaluation can influence the future direction of projects, so cytotoxicity profiling of screening libraries at an early stage is essential for increasing the likelihood of candidate success. In this study, we assessed the cell-based cytotoxicity of nearly 10,000 compounds in the National Institutes of Health, National Center for Advancing Translational Sciences annotated libraries and more than 100,000 compounds in a diversity library against four normal cell lines (HEK 293, NIH 3T3, CRL-7250, and HaCat) and one cancer cell line (KB 3-1, a HeLa subline). This large-scale library profiling was analyzed for overall screening outcomes, hit rates, pan-activity, and selectivity. For the annotated library, we also examined the primary targets and mechanistic pathways regularly associated with cell death. To our knowledge, this is the first study to use high-throughput screening to profile a large screening collection (>100,000 compounds) for cytotoxicity in both normal and cancer cell lines. The results generated here constitute a valuable resource for the scientific community and provide insight into the extent of cytotoxic compounds in screening libraries, allowing for the identification and avoidance of compounds with cytotoxicity during high-throughput screening campaigns.
Collapse
Affiliation(s)
- Olivia W. Lee
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Shelley Austin
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Madison Gamma
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Dorian M. Cheff
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Tobie D. Lee
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Kelli M. Wilson
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Joseph Johnson
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Jameson Travers
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - John C. Braisted
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Rajarshi Guha
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Carleen Klumpp-Thomas
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Min Shen
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| | - Matthew D. Hall
- National Center for Advancing Translational Sciences, National Institutes of Health, Rockville, MD, USA
| |
Collapse
|
5
|
Zhu H, Bouhifd M, Donley E, Egnash L, Kleinstreuer N, Kroese ED, Liu Z, Luechtefeld T, Palmer J, Pamies D, Shen J, Strauss V, Wu S, Hartung T. Supporting read-across using biological data. ALTEX 2016; 33:167-82. [PMID: 26863516 PMCID: PMC4834201 DOI: 10.14573/altex.1601252] [Citation(s) in RCA: 63] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 01/25/2016] [Accepted: 02/09/2016] [Indexed: 01/08/2023]
Abstract
Read-across, i.e. filling toxicological data gaps by relating to similar chemicals, for which test data are available, is usually done based on chemical similarity. Besides structure and physico-chemical properties, however, biological similarity based on biological data adds extra strength to this process. In the context of developing Good Read-Across Practice guidance, a number of case studies were evaluated to demonstrate the use of biological data to enrich read-across. In the simplest case, chemically similar substances also show similar test results in relevant in vitro assays. This is a well-established method for the read-across of e.g. genotoxicity assays. Larger datasets of biological and toxicological properties of hundreds and thousands of substances become increasingly available enabling big data approaches in read-across studies. Several case studies using various big data sources are described in this paper. An example is given for the US EPA's ToxCast dataset allowing read-across for high quality uterotrophic assays for estrogenic endocrine disruption. Similarly, an example for REACH registration data enhancing read-across for acute toxicity studies is given. A different approach is taken using omics data to establish biological similarity: Examples are given for stem cell models in vitro and short-term repeated dose studies in rats in vivo to support read-across and category formation. These preliminary biological data-driven read-across studies highlight the road to the new generation of read-across approaches that can be applied in chemical safety assessment.
Collapse
Affiliation(s)
- Hao Zhu
- Department of Chemistry and Center for Computational and Integrative Biology, Rutgers University, Camden, NJ, USA
| | - Mounir Bouhifd
- Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA
| | | | - Laura Egnash
- Stemina Biomarker Discovery Inc., Madison, WI, USA
| | - Nicole Kleinstreuer
- National Toxicology Program Interagency Center for the Evaluation of Alternative Toxicological Methods, National Institute of Environmental Health Sciences, Research Triangle Park, NC, USA
| | - E Dinant Kroese
- Risk Analysis for Products in Development, TNO Zeist, The Netherlands
| | | | - Thomas Luechtefeld
- Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA
| | | | - David Pamies
- Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA
| | - Jie Shen
- Research Institute for Fragrance Materials, Inc. Woodcliff Lake, New Jersey, USA
| | - Volker Strauss
- BASF Aktiengesellschaft, Experimental Toxicology and Ecology, Ludwigshafen, Germany
| | | | - Thomas Hartung
- Johns Hopkins Bloomberg School of Public Health, Center for Alternatives to Animal Testing (CAAT), Baltimore, MD, USA
- University of Konstanz, CAAT-Europe, Konstanz, Germany
| |
Collapse
|
6
|
Barette C, Soleilhac E, Charavay C, Cochet C, Fauvarque MO. [Strength and specificity of the CMBA screening platform for bioactive molecules discovery]. Med Sci (Paris) 2015; 31:423-31. [PMID: 25958761 DOI: 10.1051/medsci/20153104017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Used as powerful chemical probes in Life science fundamental research, the application potential of new bioactive molecular entities includes but extends beyond their development as therapeutic drugs in pharmacology. In this review, we wish to point out the methodology of chemical libraries screening on living cells or purified proteins at the CMBA academic platform of Grenoble Alpes University, and strategies employed to further characterize the selected bioactive molecules by phenotypic profiling on human cells. Multiple application fields are concerned by the screening activity developed at CMBA with bioactive molecules previously selected for their potential as tools for fundamental research purpose, therapeutic candidates to treat cancer or infection, or promising compounds for production of bioenergy.
Collapse
Affiliation(s)
- Caroline Barette
- Université Grenoble Alpes ; CEA-Direction des sciences du vivant, Institut de recherches en technologies et sciences pour le vivant, iRTSV-BGE-CMBA, CEA-Grenoble; Inserm UMRS_1038, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France
| | - Emmanuelle Soleilhac
- Université Grenoble Alpes ; CEA-Direction des sciences du vivant, Institut de recherches en technologies et sciences pour le vivant, iRTSV-BGE-CMBA, CEA-Grenoble; Inserm UMRS_1038, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France
| | - Céline Charavay
- Université Grenoble Alpes ; CEA-Direction des sciences du vivant, Institut de recherches en technologies et sciences pour le vivant, iRTSV-BGE-CMBA, CEA-Grenoble; Inserm UMRS_1038, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France
| | - Claude Cochet
- Université Grenoble Alpes ; CEA-Direction des sciences du vivant, Institut de recherches en technologies et sciences pour le vivant, BCI ; Inserm UMRS_1036, iRTSV-BCI-KIN, CEA-Grenoble, 17 rue des Martyrs, 38054 Grenoble Cedex 9, France
| | - Marie-Odile Fauvarque
- Université Grenoble Alpes ; CEA-Direction des sciences du vivant, Institut de recherches en technologies et sciences pour le vivant, iRTSV-BGE-CMBA, CEA-Grenoble; Inserm UMRS_1038, 17, rue des Martyrs, 38054 Grenoble Cedex 9, France
| |
Collapse
|
7
|
Fujii Y, Narita T, Tice RR, Takeda S, Yamada R. Isotonic Regression Based-Method in Quantitative High-Throughput Screenings for Genotoxicity. Dose Response 2015; 13:10.2203_dose-response.13-045.Fujii. [PMID: 26673567 PMCID: PMC4674159 DOI: 10.2203/dose-response.13-045.fujii] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023] Open
Abstract
Quantitative high-throughput screenings (qHTSs) for genotoxicity are conducted as part of comprehensive toxicology screening projects. The most widely used method is to compare the dose-response data of a wild-type and DNA repair gene knockout mutants, using model-fitting to the Hill equation (HE). However, this method performs poorly when the observed viability does not fit the equation well, as frequently happens in qHTS. More capable methods must be developed for qHTS where large data variations are unavoidable. In this study, we applied an isotonic regression (IR) method and compared its performance with HE under multiple data conditions. When dose-response data were suitable to draw HE curves with upper and lower asymptotes and experimental random errors were small, HE was better than IR, but when random errors were big, there was no difference between HE and IR. However, when the drawn curves did not have two asymptotes, IR showed better performance (p < 0.05, exact paired Wilcoxon test) with higher specificity (65% in HE vs. 96% in IR). In summary, IR performed similarly to HE when dose-response data were optimal, whereas IR clearly performed better in suboptimal conditions. These findings indicate that IR would be useful in qHTS for comparing dose-response data.
Collapse
Affiliation(s)
- Yosuke Fujii
- Center for Genomic Medicine, Kyoto University Graduate School of Medicine, Japan
| | - Takeo Narita
- Department of Radiation Genetics, Kyoto University Graduate School of Medicine, Japan
| | - Raymond Richard Tice
- Division of the National Toxicology Program, National Institute of Environmental Health Sciences, USA
| | - Shunich Takeda
- Department of Radiation Genetics, Kyoto University Graduate School of Medicine, Japan
| | - Ryo Yamada
- Department of Radiation Genetics, Kyoto University Graduate School of Medicine, Japan
| |
Collapse
|
8
|
Merrick BA, Paules RS, Tice RR. Intersection of toxicogenomics and high throughput screening in the Tox21 program: an NIEHS perspective. ACTA ACUST UNITED AC 2015; 14:7-27. [PMID: 27122658 DOI: 10.1504/ijbt.2015.074797] [Citation(s) in RCA: 34] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
Humans are exposed to thousands of chemicals with inadequate toxicological data. Advances in computational toxicology, robotic high throughput screening (HTS), and genome-wide expression have been integrated into the Tox21 program to better predict the toxicological effects of chemicals. Tox21 is a collaboration among US government agencies initiated in 2008 that aims to shift chemical hazard assessment from traditional animal toxicology to target-specific, mechanism-based, biological observations using in vitro assays and lower organism models. HTS uses biocomputational methods for probing thousands of chemicals in in vitro assays for gene-pathway response patterns predictive of adverse human health outcomes. In 1999, NIEHS began exploring the application of toxicogenomics to toxicology and recent advances in NextGen sequencing should greatly enhance the biological content obtained from HTS platforms. We foresee an intersection of new technologies in toxicogenomics and HTS as an innovative development in Tox21. Tox21 goals, priorities, progress, and challenges will be reviewed.
Collapse
Affiliation(s)
- B Alex Merrick
- Biomolecular Screening Branch, Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
| | - Richard S Paules
- Biomolecular Screening Branch, Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
| | - Raymond R Tice
- Biomolecular Screening Branch, Division of the National Toxicology Program, National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina, USA
| |
Collapse
|
9
|
Abstract
Quantitative structure activity relationship (QSAR) is the most frequently used modeling approach to explore the dependency of biological, toxicological, or other types of activities/properties of chemicals on their molecular features. In the past two decades, QSAR modeling has been used extensively in drug discovery process. However, the predictive models resulted from QSAR studies have limited use for chemical risk assessment, especially for animal and human toxicity evaluations, due to the low predictivity of new compounds. To develop enhanced toxicity models with independently validated external prediction power, novel modeling protocols were pursued by computational toxicologists based on rapidly increasing toxicity testing data in recent years. This chapter reviews the recent effort in our laboratory to incorporate the biological testing results as descriptors in the toxicity modeling process. This effort extended the concept of QSAR to quantitative structure in vitro-in vivo relationship (QSIIR). The QSIIR study examples provided in this chapter indicate that the QSIIR models that based on the hybrid (biological and chemical) descriptors are indeed superior to the conventional QSAR models that only based on chemical descriptors for several animal toxicity endpoints. We believe that the applications introduced in this review will be of interest and value to researchers working in the field of computational drug discovery and environmental chemical risk assessment.
Collapse
Affiliation(s)
- Hao Zhu
- Department of Chemistry, The Rutgers Center for Computational and Integrative Biology, Rutgers University, 315 Penn St., Camden, NJ, 08102, USA.
| |
Collapse
|
10
|
Pireddu R, Forinash KD, Sun NN, Martin MP, Sung SS, Alexander B, Zhu JY, Guida WC, Schönbrunn E, Sebti SM, Lawrence NJ. Pyridylthiazole-based ureas as inhibitors of Rho associated protein kinases (ROCK1 and 2). MEDCHEMCOMM 2012; 3:699-709. [PMID: 23275831 PMCID: PMC3531244 DOI: 10.1039/c2md00320a] [Citation(s) in RCA: 41] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/01/2023]
Abstract
Potent ROCK inhibitors of a new class of 1-benzyl-3-(4-pyridylthiazol-2-yl)ureas have been identified. Remarkable differences in activity were observed for ureas bearing a benzylic stereogenic center. Derivatives with hydroxy, methoxy and amino groups at the meta position of the phenyl ring give rise to the most potent inhibitors (low nM). Substitutions at the para position result in substantial loss of potency. Changes at the benzylic position are tolerated resulting in significant potency in the case of methyl and methylenehydroxy groups. X-Ray crystallography was used to establish the binding mode of this class of inhibitors and provides an explanation for the observed differences of the enantiomer series. Potent inhibition of ROCK in human lung cancer cells was shown by suppression of the levels of phosphorylation of the ROCK substrate MYPT-1.
Collapse
Affiliation(s)
- Roberta Pireddu
- The Department of Drug Discovery, Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, Florida, 33612, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Ogawa Y, Hagiwara M. Challenges to congenital genetic disorders with “RNA-targeting” chemical compounds. Pharmacol Ther 2012; 134:298-305. [DOI: 10.1016/j.pharmthera.2012.02.001] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/23/2012] [Accepted: 01/24/2012] [Indexed: 11/16/2022]
|
12
|
Sun H, Xia M, Austin CP, Huang R. Paradigm shift in toxicity testing and modeling. AAPS JOURNAL 2012; 14:473-80. [PMID: 22528508 DOI: 10.1208/s12248-012-9358-1] [Citation(s) in RCA: 56] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/14/2011] [Accepted: 04/05/2012] [Indexed: 12/11/2022]
Abstract
The limitations of traditional toxicity testing characterized by high-cost animal models with low-throughput readouts, inconsistent responses, ethical issues, and extrapolability to humans call for alternative strategies for chemical risk assessment. A new strategy using in vitro human cell-based assays has been designed to identify key toxicity pathways and molecular mechanisms leading to the prediction of an in vivo response. The emergence of quantitative high-throughput screening (qHTS) technology has proved to be an efficient way to decompose complex toxicological end points to specific pathways of targeted organs. In addition, qHTS has made a significant impact on computational toxicology in two aspects. First, the ease of mechanism of action identification brought about by in vitro assays has enhanced the simplicity and effectiveness of machine learning, and second, the high-throughput nature and high reproducibility of qHTS have greatly improved the data quality and increased the quantity of training datasets available for predictive model construction. In this review, the benefits of qHTS routinely used in the US Tox21 program will be highlighted. Quantitative structure-activity relationships models built on traditional in vivo data and new qHTS data will be compared and analyzed. In conjunction with the transition from the pilot phase to the production phase of the Tox21 program, more qHTS data will be made available that will enrich the data pool for predictive toxicology. It is perceivable that new in silico toxicity models based on high-quality qHTS data will achieve unprecedented reliability and robustness, thus becoming a valuable tool for risk assessment and drug discovery.
Collapse
Affiliation(s)
- Hongmao Sun
- Department of Health and Human Services, NIH Chemical Genomics Center, National Institutes of Health, Bethesda, Maryland 20892-3370, USA.
| | | | | | | |
Collapse
|
13
|
Recent trends in statistical QSAR modeling of environmental chemical toxicity. EXPERIENTIA SUPPLEMENTUM (2012) 2012; 101:381-411. [PMID: 22945576 DOI: 10.1007/978-3-7643-8340-4_13] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
Quantitative cheminformatics approaches such as QSAR modeling find growing applications in chemical risk assessment. Traditional methods rely on the use of calculated chemical descriptors of molecules and relatively small training sets. However, in recent years, there is a trend toward the increased use of in vitro biological testing approaches to reduce both the length of experimental studies and the animal use for chemical risk assessment. Furthermore, there is also much greater emphasis on model validation using external datasets to enable the reliable use of computational models as part of regulatory decision making. In this chapter, recent trends emphasizing the need for both careful curation of experimental data prior to model development and rigorous model validation are investigated. Furthermore, recent approaches to chemical toxicity prediction that employ both chemical descriptors and in vitro screening data for developing novel hybrid chemical/biological models are being reviewed. Examples of respective application studies that employ novel workflows for model developments are described and recent important efforts by several academic, nonprofit, and industrial groups to start placing both data and, especially, models in the public domain are discussed.
Collapse
|
14
|
Huang R, Southall N, Wang Y, Yasgar A, Shinn P, Jadhav A, Nguyen DT, Austin CP. The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics. Sci Transl Med 2011; 3:80ps16. [PMID: 21525397 PMCID: PMC3098042 DOI: 10.1126/scitranslmed.3001862] [Citation(s) in RCA: 311] [Impact Index Per Article: 23.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Small-molecule compounds approved for use as drugs may be "repurposed" for new indications and studied to determine the mechanisms of their beneficial and adverse effects. A comprehensive collection of all small-molecule drugs approved for human use would be invaluable for systematic repurposing across human diseases, particularly for rare and neglected diseases, for which the cost and time required for development of a new chemical entity are often prohibitive. Previous efforts to build such a comprehensive collection have been limited by the complexities, redundancies, and semantic inconsistencies of drug naming within and among regulatory agencies worldwide; a lack of clear conceptualization of what constitutes a drug; and a lack of access to physical samples. We report here the creation of a definitive, complete, and nonredundant list of all approved molecular entities as a freely available electronic resource and a physical collection of small molecules amenable to high-throughput screening.
Collapse
Affiliation(s)
| | | | - Yuhong Wang
- NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD 20892
| | - Adam Yasgar
- NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD 20892
| | - Paul Shinn
- NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD 20892
| | - Ajit Jadhav
- NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD 20892
| | - Dac-Trung Nguyen
- NIH Chemical Genomics Center, National Institutes of Health, Bethesda, MD 20892
| | | |
Collapse
|
15
|
Judson RS, Kavlock RJ, Setzer RW, Cohen Hubal EA, Martin MT, Knudsen TB, Houck KA, Thomas RS, Wetmore BA, Dix DJ. Estimating Toxicity-Related Biological Pathway Altering Doses for High-Throughput Chemical Risk Assessment. Chem Res Toxicol 2011; 24:451-62. [DOI: 10.1021/tx100428e] [Citation(s) in RCA: 165] [Impact Index Per Article: 12.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022]
Affiliation(s)
- Richard S. Judson
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - Robert J. Kavlock
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - R. Woodrow Setzer
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - Elaine A. Cohen Hubal
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - Matthew T. Martin
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - Thomas B. Knudsen
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - Keith A. Houck
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| | - Russell S. Thomas
- The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, United States
| | - Barbara A. Wetmore
- The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, United States
| | - David J. Dix
- National Center for Computational Toxicology, Office of Research and Development, U.S. Environmental Protection Agency, Research Triangle Park, North Carolina 27711, United States
| |
Collapse
|
16
|
Shukla SJ, Huang R, Austin CP, Xia M. The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform. Drug Discov Today 2010; 15:997-1007. [PMID: 20708096 DOI: 10.1016/j.drudis.2010.07.007] [Citation(s) in RCA: 172] [Impact Index Per Article: 12.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2010] [Revised: 06/08/2010] [Accepted: 07/30/2010] [Indexed: 01/16/2023]
Abstract
The US Tox21 collaborative program represents a paradigm shift in toxicity testing of chemical compounds from traditional in vivo tests to less expensive and higher throughput in vitro methods to prioritize compounds for further study, identify mechanisms of action and ultimately develop predictive models for adverse health effects in humans. The NIH Chemical Genomics Center (NCGC) is an integral component of the Tox21 collaboration owing to its quantitative high-throughput screening (qHTS) paradigm, in which titration-based screening is used to profile hundreds of thousands of compounds per week. Here, we describe the Tox21 collaboration, qHTS-based compound testing and the various Tox21 screening assays that have been validated and tested at the NCGC to date.
Collapse
Affiliation(s)
- Sunita J Shukla
- NIH Chemical Genomics Center, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892-3370, USA
| | | | | | | |
Collapse
|